Liver Fat Changes in Patients With Type 2 Diabetes by Presence of Genetic Hepatic Steatosis: A Post Hoc Analysis of SURPASS-3 MRI.

Liver IntSep 1, 2026
Clinical ResearchEndocrinologyGastroenterologyOpen access

Kenneth Cusi, Amalia Gastaldelli, Laura Fernández Landó et al.

✦ AI-curated · Sources linked

In 30 seconds

This post hoc analysis of the SURPASS-3 MRI trial examined the impact of the PNPLA3 I148M genetic variant on liver fat content (LFC) changes in insulin-naïve patients with type 2 diabetes treated with tirzepatide. The study found that tirzepatide significantly reduced LFC, weight, and HbA1c, with improvements observed regardless of the PNPLA3 genotype.

Key findings

  • Tirzepatide reduced liver fat content significantly compared to insulin degludec.
  • Participants showed improvements in weight and HbA1c after 52 weeks of treatment.
  • The presence of the PNPLA3 I148M allele did not affect LFC changes.
  • Improvements in lipids and liver enzymes were consistent across genotype subgroups.

Why it matters

Understanding the genetic factors influencing treatment response in type 2 diabetes can help tailor therapies. This study suggests that tirzepatide's efficacy in reducing liver fat is independent of the PNPLA3 I148M variant, which may simplify treatment decisions.

Source

PubMed · PMID 42576670Free full text on PubMed Central

Published in Liver Int. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Endocrinology

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.